Recent developments in ocular allergy

Clinical Eye and Vision Care

Volumn 11, Issue 1, 1999, Pages 37-39

  Nehmad, Leon ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CELL ADHESION MOLECULE; CORTICOSTEROID; CYCLOSPORIN; EMEDASTINE; INTERCELLULAR ADHESION MOLECULE 1; LEVOCABASTINE; LOTEPREDNOL ETABONATE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PATENOL; PENTIGETIDE; STABILIZING AGENT; SUBSTANCE P; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ALLERGY; DISEASE CLASSIFICATION; EOSINOPHIL; EYE DISEASE; MAST CELL; SEASONAL VARIATION; SHORT SURVEY; VERNAL CONJUNCTIVITIS;

EID: 0032938750     PISSN: 09534431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-4431(99)00009-0     Document Type: Article

References (26)

1. Foster SC The pathophysiology of ocular allergy: current thinking. Allergy. 50:1995;6-9.
2. Friedlaender MH. Allergy and immunology of the eye. 2nd ed. New York: Raven Press, 1993.
3. Shovlin JP, Boland BS, DePaolis MD Ocular allergy and contact lens wear: signs, symptoms, and solutions. Contact Lens Spectrum. 13:1998;23-33.
4. Smolin G Ocular allergy: the third annual Thygeson lecture, presented at the ocular microbiology and immunology group meeting, October 25, 1997. Cornea. 17:1998;253-256.
5. Jaanus SD Oral and topical antihistamines: pharmacologic properties and therapeutic potential in ocular allergic disease. J Am Optom Assoc. 69:1998;77-85.
6. 1 antagonist for topical ocular use. J Ocul Pharmacol. 10:1994;665-675.
7. El-Defrawy S, Jackson WB New directions in therapy for ocular allergy. Int Ophthalmol Clin. 36:1996;25-44.
8. 1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis. J Ocular Pharmacol Ther. 12:1996;401-407.
9. Yanni JM, Miller ST, Gamache DAet al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 79:1997;541-545.
10. Dell SJ, Lowry GM, Northcutt JAet al. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 102:1998;251-255.
11. Dell SJ, Shulman DG, Lowry GMet al. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Am J Ophthalmol. 123:1997;791-797.
12. Friedlaender MH, Howes J A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Am J Ophthalmol. 123:1997;455-464.
13. El-Asrar AM, Tabbara KF, Geboes Ket al. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol. 121:1996;156-161.
14. Hingorani M, Moodaley L, Calder VLet al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 105:1998;1715-1720.
15. El-Asrar AM, Geboes K, Al-Kharashi Set al. Adhesion molecules in vernal keratoconjunctivitis. Br J Ophthalmol. 81:1997;1099-1106.
16. Gill KS, Yannariello-Brown J, Patel Jet al. ICAM-1 expression in corneal epithelium of a patient with vernal keratoconjunctivitis. Cornea. 16:1997;107-111.
17. Canonica GW, Ciprandi G, Passalacqua Get al. Molecular events in allergic inflammation: experimental models and possible modulation. Allergy. 52:1997;25-40.
18. National Eye Institute, Intramural Research, web site.
19. Hingorani M, Calder V, Jolly Get al. Eosinophil surface antigen expression and cytokine production vary in different ocular allergic diseases. J Allergy Clin Immunol. 102:1998;821-830.
20. El-Shazly AE, Masuyama K, Samejima Yet al. Inhibition of human eosinophil chemotaxis in vitro by the anti-allergic agent emedastine difumarate. Immunopharmacol Immunotoxicol. 18:1996;587-595.
21. Bonini S, Magrini L, Rotiroti Get al. The eosinophil and the eye. Allergy. 52:1997;44-47.
22. Kalpaxis JG, Thayer TO Double-bind trial of pentigetide ophthalmic solution, 0.5%, compared with cromolyn sodium, 4% ophthalmic solution for allergic conjunctivitis. Ann Allergy. 66:1991;393-398.
23. Bennich H, Ragnarsson U, Johansson SGet al. Failure of the putative IgE pentapeptide to compete with IgE for receptors on basophils and mast cells. Int Arch Allergy App Immunol. 53:1977;459-468.
24. Bielory L. Notes from annual meeting of American academy of allergy, asthma and immunology, February 1997. In: Allergic diseases of the eye - mediconsult.com web site.
25. Fujishima H, Takeyama M, Takeuchi Tet al. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal conjunctivitis. Clin Exp Allergy. 27:1997;372-378.
26. Saito T, Hagihara A, Igarashi N Inhibitory effects of emedastine difumarate on histamine release. Jpn J Pharmacol. 62:1993;137-143.